Home National

National

Biocon Receives Marketing Authorization for its Novel Biologic Itolizumab for Psoriasis

Bangalore, Karnataka, India, Tuesday, January 08, 2013 -- (Business Wire India) -- Biocon, Asia's premier biotechnology company today announced that it has received Marketing Authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis.

Itolizumab, is a first in class therapy with a unique Mechanism of Action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. It is the second Novel Biologic developed by Biocon at Asia's largest Biotech hub in Bangalore.

Ranbaxy Launches Authorized Generic of Evoxac in the U.S. Healthcare Market

Gurgaon , India , Princeton , New Jersey

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (Ranbaxy), has launched the authorized generic cevimeline hydrochloride 30 mg. capsules in the U.S. market, under an agreement with Daiichi Sankyo, Inc.

Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren's syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently distributed by Daiichi Sankyo, Inc. under the brand name Evoxac ® . Evoxac ®   generated total annualized sales of $62.4 million in the U.S. (IMS – MAT June 2012).

Bill Winter, Vice President, Trade Sales and Distribution, North America, Ranbaxy said, “Ranbaxy is pleased to announce the launch of cevimeline hydrochloride in 30 mg. capsules, as the authorized generic of  Evoxac ®   in the U.S.  This launch further underscores Ranbaxy's resolve to bring high quality, affordable generic medicines to the U.S. healthcare system to meet the growing needs of patients and prescribers.”

TTK Healthcare board approves merger of arms

MUMBAI, MAY 3:

The board of TTK Healthcare has approved a scheme of amalgamation of TTK Protective Devices, formerly known as TTK-LIG, an unlisted public company, and TSL Techno Services (TSL), a wholly-owned subsidiary of TTK Protective Devices, with itself.

TTK Protective Devices is a contraceptive (condom-making) company with a capacity of two billion condoms.

The shareholders of TTK Protective Devices (TTKPD) are to get nine equity shares of Rs 10 each fully paid up of TTK Healthcare, for every two shares of Rs 10 each fully paid up held by them in TTKPD, thus leading to an equity dilution of 82 per cent.